The Hemoglobin Level as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer Treated with Gemcitabine and cis-Platinum

To analyze and describe a series of patients with non- small cell lung cancer treated with erlotinib during a period prior to the mandatory investigation of the epidermal

The aim of this study was to evaluate the frequency of epidermal growth factor receptor and KRAS mutations in a population of Brazilian patients with non-small cell lung

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung

(2015) Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with

Objectives: To determine differences in overall survival and quality of life among patients with stage IV non-small cell lung cancer non-metastatic to the brain treated with

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern

Survival and prognostic factors in patients with Non-Small Cell Lung Cancer treated in private health care.. Sobrevida e fatores prognósticos em pacientes com câncer de pulmão de